Table 3.
Comparison between EGFR mutation (L858R) status analysis by DHPLC, ME-Liquidchip, and Scorpion-ARMS in peripheral blood and Scorpion-ARMS in tumor tissue
| No | Scorpion-ARMS in T | Total | |
|---|---|---|---|
|
|
|||
| (+) | (−) | ||
| DHPLC in B | |||
| (+) | 2 | 2 | 4 |
| (−) | 6 | 24 | 30 |
| Total | 8 | 26 | 34 |
| Scorpion-ARMS in B | |||
| (+) | 4 | 0 | 4 |
| (−) | 4 | 26 | 30 |
| Total | 8 | 26 | 34 |
| ME-Liquidchip in B | |||
| (+) | 2 | 1 | 3 |
| (−) | 6 | 25 | 31 |
| Total | 8 | 26 | 34 |
Abbreviations: EGFR, epidermal growth factor receptor; L858R, exon 21 mutation of EGFR; DHPLC, denaturing high-performance liquid chromatography; ME-Liquidchip, mutant-enriched liquidchip; Scorpion-ARMS, Scorpion Amplification Refractory Mutation System; T, tumor tissue; B, peripheral blood; M+, mutation positive; M-, mutation negative.